Medical News

RSS

Geron commences GRNOPC1 hESC-based cell therapy in patients with spinal cord injury

Geron Corporation today announced the enrollment of the first patient in the company's clinical trial of human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells, GRNOPC1. The primary objective of this Phase I study is to assess the safety and tolerability of GRNOPC1 in patients with "complete" American Spinal Injury Association (ASIA) Impairment Scale grade A thoracic spinal cord injuries. Participants in the study must be newly injured and receive GRNOPC1 within 14 days of the injury.

11 Oct 2010

The Atlantic reports on potential challenges to passage of the International Violence Against Women Act

The Atlantic looks at the challenges facing the passage of I-VAWA (S.2982, HR. 4594), or the International Violence Against Women Act, which was recently delayed in Congress.

11 Oct 2010

Researchers to convene for 2010 Advances in Breast Cancer Research Workshop at University of Arkansas

Leading national researchers in the fight against breast cancer will convene Oct. 26-29 for the 2010 Advances in Breast Cancer Research Workshop at the University of Arkansas. More than 70 scientists from diverse research areas in science, medicine, engineering and technology will participate. Ten featured speakers will present cutting-edge research on breast cancer diagnosis, therapeutic techniques, treatment and screening.

11 Oct 2010

NIH selects Neil Chi for 2010 New Innovator Award

The National Institutes of Health has chosen Neil Chi, MD, PhD, assistant professor of medicine in the division of cardiology at the University of California, San Diego, as one of its 2010 NIH Director's New Innovator Award recipients.

11 Oct 2010

Weikang Bio-Technology reiterates fiscal 2010 revenue guidance, targets growth of 30% to 50% for fiscal 2011

Weikang Bio-Technology Group Co., Inc., a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that the Company is reiterating its fiscal 2010 revenue guidance of $55 million, net profit of $21 million and earning per share of $0.75.

11 Oct 2010

Valeant announces Alexza's receipt of FDA CRL for AZ-004 NDA

Valeant Pharmaceuticals International, Inc. announced today that Alexza Pharmaceuticals, Inc. has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Alexza's New Drug Application (NDA) for AZ-004 (Staccato® loxapine) submitted as Adusuve™ Staccato® (loxapine) inhalation aerosol, 5 mg and 10 mg.

11 Oct 2010

Novel hormonal treatments may help ER-negative breast cancer patients: Study

Women who have estrogen (ER) negative breast cancer may have more drug treatment options than previously thought, a Creighton (pronounced Cray-ton) University study suggests. The study is reported in the Oct. 11 online version of the journal Oncogene.

11 Oct 2010

PlastiPure, ReliaBrand partner to produce EA-Free plastic consumer products

PlastiPure, a safer-plastics technology company, has announced a partnership with ReliaBrand to license infant feeding, sports bottle, food packaging, and medical products free of harmful chemicals that cause estrogenic activity (EA). Chemicals with EA have been strongly linked to adverse health effects such as birth defects, reproductive cancers, and behavioral and learning disorders. The widely known chemicals BPA and phthalates are only a few of thousands of chemicals suspected to have EA.

11 Oct 2010

The age wave could bust government budgets, rating agency says

The ratings agency Standard & Poor's has joined the chorus of concern about how the looming age wave will affect governments that must pay for escalating entitlement programs, The Wall Street Journal reports.

11 Oct 2010

Sec. of State Clinton, other officials launch initiative to provide mobile phones to 150M women in the developing world

Officials gathered in Washington, D.C. on Thursday to launch mWomen, an initiative aimed at increasing access to mobile phones to further health and development benefits among women in the developing countries, the Telegraph reports.

11 Oct 2010

ACT Biotech reports positive interim data from Telatinib Phase 2 trial for advanced gastric cancer

ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.

11 Oct 2010

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Eli Lilly and Company announced today that its global Phase III trial evaluating ALIMTA (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) did not meet its primary endpoint for overall survival. Data were presented for the first time today at the 35th Annual Meeting of the European Society for Medical Oncology (ESMO).

11 Oct 2010

ArQule announces ARQ 197 Phase 2 clinical trial results at ESMO annual meeting

ArQule, Inc. today announced the presentation of final results from a Phase 2 clinical trial in non-small cell lung cancer (NSCLC) of ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, at the annual meeting of the European Society for Medical Oncology (ESMO).

11 Oct 2010

NBM 200 system accurately measures hemoglobin level

OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, presented today at the AABB Annual Meeting & CTTXPO 2010, in Baltimore, Maryland, results showing that hemoglobin (Hb) measurements obtained by its NBM 200, a non-invasive Hb measurement system for anemia screening, showed accurate performance compared with invasive point of care (POC) devices.

11 Oct 2010

ALung Technologies announces closing of $14 Million Series A financing round

ALung Technologies, Inc. today announced that the Company has closed a $14 Million Series A financing round. The investment will support ongoing clinical trials of the Hemolung™ Respiratory Assist System and its subsequent commercialization. The Company's Hemolung device is expected to help many patients with acute respiratory failure to avoid intubation and invasive mechanical ventilation.

11 Oct 2010

Part of brain reorganizes to enhance visual abilities in deaf cats

Deaf or blind people often report enhanced abilities in their remaining senses, but up until now, no one has explained how and why that could be. Researchers at The University of Western Ontario, led by Stephen Lomber of The Centre for Brain and Mind have discovered there is a causal link between enhanced visual abilities and reorganization of the part of the brain that usually handles auditory input in congenitally deaf cats. The findings, published online in Nature Neuroscience, provide insight into the plasticity that may occur in the brains of deaf people.

11 Oct 2010

Allos announces favorable survival data from FOLOTYN Phase 2b study

Allos Therapeutics, Inc. today announced the presentation of favorable survival data from the Company's international, randomized Phase 2b investigational study of FOLOTYN relative to erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC). In this study, patients receiving FOLOTYN had a 16 percent reduction in the risk of death compared to erlotinib in the overall (intent-to-treat) population.

11 Oct 2010

MOH approves BrainStorm's NurOwn stem cell therapy for Phase I/II clinical trial

BrainStorm Cell Therapeutics Inc. a leading developer of adult stem cell technologies and therapeutics, today announced that the Israeli Ministry of Health (MOH) has granted clearance for a Phase I/II clinical trial using the company's autologous NurOwn stem cell therapy in patients with amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's Disease.

11 Oct 2010

BioSante presents update on LibiGel clinical study at NAMS Annual Meeting

BioSante Pharmaceuticals, Inc. presented a LibiGel clinical study update at the 21st Annual Meeting of The North American Menopause Society (NAMS) on October 8, 2010, with more than 1,000 experts and practitioners in menopause and women's health in attendance.

11 Oct 2010

More than 2 hours of screen viewing associated with psychological difficulties in children

Children who spend longer than two hours in front of a computer or television screen are more likely to suffer psychological difficulties, regardless of how physically active they are.

11 Oct 2010

Medical News

Geron commences GRNOPC1 hESC-based cell therapy in patients with spinal cord injury

The Atlantic reports on potential challenges to passage of the International Violence Against Women Act

Researchers to convene for 2010 Advances in Breast Cancer Research Workshop at University of Arkansas

NIH selects Neil Chi for 2010 New Innovator Award

Weikang Bio-Technology reiterates fiscal 2010 revenue guidance, targets growth of 30% to 50% for fiscal 2011

Valeant announces Alexza's receipt of FDA CRL for AZ-004 NDA

Novel hormonal treatments may help ER-negative breast cancer patients: Study

PlastiPure, ReliaBrand partner to produce EA-Free plastic consumer products

The age wave could bust government budgets, rating agency says

Sec. of State Clinton, other officials launch initiative to provide mobile phones to 150M women in the developing world

ACT Biotech reports positive interim data from Telatinib Phase 2 trial for advanced gastric cancer

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

ArQule announces ARQ 197 Phase 2 clinical trial results at ESMO annual meeting

NBM 200 system accurately measures hemoglobin level

ALung Technologies announces closing of $14 Million Series A financing round

Part of brain reorganizes to enhance visual abilities in deaf cats

Allos announces favorable survival data from FOLOTYN Phase 2b study

MOH approves BrainStorm's NurOwn stem cell therapy for Phase I/II clinical trial

BioSante presents update on LibiGel clinical study at NAMS Annual Meeting

More than 2 hours of screen viewing associated with psychological difficulties in children

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

The importance of ketones from a clinical and medical perspective

Latest News